Investing.com - Financial Markets Worldwide

Organon Pharma (SCPI)

Jakarta
Currency in IDR
29,000.00
0.00(0.00%)
Closed·

SCPI Financial Summary

Key Ratios

P/E Ratio0
Price/Book0
Debt / Equity0.21%
Return on Equity22.01%
Dividend Yield0.00%
EBITDA261.15B
Fair ValueUnlock
Fair Value UpsideUnlock

Statements Highlights

Period Ending:
2015
31/12
2016
31/12
2017
31/12
2018
31/12
2019
31/12
2020
31/12
2021
31/12
2022
31/12
2023
31/12
2024
31/12
Income Statement
Total Revenues
aa.aaaa.aaaa.aaaa.aaaa.aa2,893,298.082,159,191.252,339,387.762,747,529.522,895,902.37
Gross Profit
aa.aaaa.aaaa.aaaa.aaaa.aa429,214.92212,469.75261,973.05297,766.34300,762.82
Operating Income
aa.aaaa.aaaa.aaaa.aaaa.aa273,253.75156,614.61218,304.02239,657.93234,572.5
Net Income
aa.aaaa.aaaa.aaaa.aaaa.aa218,362.87118,691.58174,782.1187,701.8186,615.63
Balance Sheet
Total Assets
aa.aaaa.aaaa.aaaa.aaaa.aa1,598,281.521,212,160.541,361,427.271,421,347.081,635,971.37
Total Current Liabilities
aa.aaaa.aaaa.aaaa.aaaa.aa740,613.21204,349.76343,778.94543,197.62568,972.97
Total Equity
aa.aaaa.aaaa.aaaa.aaaa.aa832,209.16972,552.47985,337.4840,447.61,033,004.23
Cash Flow
Levered Free Cash Flow
aa.aaaa.aaaa.aaaa.aaaa.aa362,169.68368,497.714,401.61232,850.54-49,733.28
Cash from Operations
aa.aaaa.aaaa.aaaa.aaaa.aa278,374.15461,426.08187,341.98313,682.1549,835.38
Cash from Investing
aa.aaaa.aaaa.aaaa.aaaa.aa-38,719.49-1,364.77-12,227.49-24,661.12-54,566
Cash from Financing
aa.aaaa.aaaa.aaaa.aaaa.aa-223,000-353,487.74-162,098.11-329,951.87-2,579.48
Net Change in Cash
aa.aaaa.aaaa.aaaa.aaaa.aa16,654.67106,573.5713,016.38-40,930.85-8,963.41
* In Millions of IDR (except for per share items)

Earnings

Latest Release
May 02, 2025
EPS / Forecast
22,570.00 / --
Revenue / Forecast
886.31B / --
EPS Revisions
a
a
Unlock
Last 90 days

FAQ

What were Organon Pharma's earnings for the latest quarter?

The Organon Pharma EPS (TTM) is 61,209.89. Organon Pharma reported sales of 886,306.99, net income of 81,254.56, and EPS of 22,570.00 for the latest quarter.

What was Organon Pharma's net income for the latest quarter?

Organon Pharma's net income for the latest quarter was 81,254.56.

How did Organon Pharma's performance compare year-over-year in the latest quarter?

The company's revenue moved from 640,937.41 in the previous quarter to 886,306.99 in the latest quarter, and net income moved from 6,639.07 to 81,254.56 compared to the previous quarter.

What is Organon Pharma's net profit margin on a TTM basis?

Organon Pharma's trailing twelve months (TTM) net profit margin is 6.44%.

How does Organon Pharma's debt to equity ratio compare to industry standards?

Organon Pharma's total debt-to-equity ratio is 0.21%.

What is Organon Pharma's return on investment on a TTM basis?

Organon Pharma's trailing twelve months (TTM) return on investment (ROI) is 22.01%.

Did Organon Pharma gain or lose cash last quarter?

In the latest quarter, Organon Pharma's net change in cash was 44,042.91 million.

What were Organon Pharma's total assets and liabilities in the latest quarter?

As of the latest quarter, Organon Pharma reported total assets of 1,924,278.81 million and total liabilities of 774,987.55 million.

How has Organon Pharma's total revenue grown this year?

Organon Pharma's total revenue was 640,937.41 in the previous quarter and 886,306.99 in the latest quarter.

What is Organon Pharma's gross margin on a TTM basis?

Organon Pharma's trailing twelve months (TTM) gross margin is 10.39%.

What was Organon Pharma's revenue per share for the latest quarter?

Organon Pharma's revenue per share for the latest quarter was 2,242.92.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.